Clinical Trials | December 09, 2025
Pharvaris’ deucrictibant shows rapid relief for hereditary angioedema in pivotal Phase 3 trial
The study met its primary endpoint and all 11 secondary efficacy endpoints
The study met its primary endpoint and all 11 secondary efficacy endpoints
It's a development that marks a potential breakthrough for people living with the rare and debilitating disease Duchenne muscular dystrophy (DMD)
Freenome expects the combined company to receive approximately $330 million in proceeds at closing
Captured microbes are then neutralized on engineered microbicidal surfaces
76 of 180 long COVID-associated genes also linked to ME
_Logo_256_384.png){kind=logo}
The Vital Shape panels provide tiered assessments to detect obesity-related risks early
The EMBOLD study evaluated relutrigine for patients with SCN2A and SCN8A developmental and epileptic encephalopathies
It's an acquisition that aims at forming one of the US's largest oncology trial networks
Biocon will acquire the residual stake held by Mylan (Viatris) for a total consideration of US$ 815 million
Valorum will advance the commercialization and distribution of Armlupeg in the United States
Subscribe To Our Newsletter & Stay Updated
